October 09, 2026 10:51 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Bold and inventive’: Canadian poet Anne Carson wins 2026 Nobel Prize in Literature | ‘Attempt to destabilise world’s largest democracy’: 42 retired judges rally behind Gyanesh Kumar over ‘vote chori’ row | ‘Vote chor, gaddi chod’: Dhruv Rathee, Prakash Raj join Bengaluru protest against Gyanesh Kumar | India condemns Houthi attacks on Saudi airports, calls targeting of civilian infrastructure unacceptable | Dalal Street bloodbath: Investors lose Rs. 8 lakh crore as Sensex crashes over 1,000 points | Amazon layoffs hit India, US and UK: Fresh job cuts rock e-commerce giant amid festive shopping season | Bollywood mourns Nana Patekar: Anupam Kher, Akshay Kumar, Jr NTR, Suniel Shetty pay emotional tributes | ‘He was never wavering while expressing his opinions’: PM Modi mourns Nana Patekar | Nana Patekar dies at 75: Veteran actor suffers cardiac arrest at Goa home | RBI shocks borrowers with first repo rate hike since 2023; rates raised to 5.50%
Russia Vaccine

Russia's RDIF confirms plans to sell 100mln doses of COVID-19 vaccine to India

| @indiablooms | Sep 16, 2020, at 09:33 pm

Moscow/Sputnik: The Russian Direct Investment Fund (RDIF) confirmed on Wednesday reaching an agreement to deliver 100 million doses of the Russian COVID-19 vaccine Sputnik V to India, specifying that the deal was reached with India's Dr. Reddy's.

Earlier in the day, a source told Sputnik that the RDIF would deliver 100 million doses of the vaccine to an Indian pharmaceutical company.

"The RDIF, Russia’s sovereign wealth fund, and Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddy’s 100 million doses of the vaccine," the RDIF said in a press release.

Deliveries could start in late 2020, the RDIF added.

A request for approval for the Phase 3 trials in India "will be filed shortly" to India's drug regulator, a RDIF spokesman told reporters.

"We are pleased to partner with RDIF to bring the vaccine to India. The Phase I and II results have shown promise, and we will be conducting Phase-III trials in India to meet the requirements of the Indian regulators. Sputnik V vaccine could provide a credible option in our fight against COVID 19 in India," Dr. Reddy's Co-Chairman and Managing Director G. V. Prasad said, as quoted in the press release.

The RDIF is pleased to reach the agreement with the Indian company, RDIF CEO Kirill Dmitriev said.

"Dr. Reddy’s has had a very well established and respected presence in Russia for over 25 years and is one of the leading pharmaceutical companies in India. India is amongst most severely impacted countries from COVID 19 and we believe our human adenovirus dual vector platform will provide a safe and scientifically validated option to India in the battle against COVID 19. RDIF partners will receive an effective and safe drug to fight the coronavirus," Dmitriev said.

In August, Russia registered the world’s first COVID-19 vaccine, developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.